日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling

在CD20/CD3双特异性抗体mosunetuzumab治疗非霍奇金淋巴瘤的I期临床试验中,降低细胞因子释放综合征的风险:转化系统建模的影响

Hosseini, Iraj; Gadkar, Kapil; Stefanich, Eric; Li, Chi-Chung; Sun, Liping L; Chu, Yu-Waye; Ramanujan, Saroja

An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia

用于治疗急性髓系白血病的抗 CD3/抗 CLL-1 双特异性抗体

Steven R Leong, Siddharth Sukumaran, Maria Hristopoulos, Klara Totpal, Shannon Stainton, Elizabeth Lu, Alfred Wong, Lucinda Tam, Robert Newman, Brian R Vuillemenot, Diego Ellerman, Chen Gu, Mary Mathieu, Mark S Dennis, Allen Nguyen, Bing Zheng, Crystal Zhang, Genee Lee, Yu-Waye Chu, Rodney A Prell, 

Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

抗CD22抗体药物偶联物Pinatuzumab Vedotin联合/不联合利妥昔单抗治疗复发/难治性B细胞非霍奇金淋巴瘤患者的I期研究

Advani, Ranjana H; Lebovic, Daniel; Chen, Andy; Brunvand, Mark; Goy, Andre; Chang, Julie E; Hochberg, Ephraim; Yalamanchili, Sreeni; Kahn, Robert; Lu, Dan; Agarwal, Priya; Dere, Randall C; Hsieh, Hsin-Ju; Jones, Surai; Chu, Yu-Waye; Cheson, Bruce D

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer

曲妥珠单抗-美坦新(T-DM1)的临床药理学:一种正在研发用于治疗HER2阳性癌症的抗体药物偶联物

Girish, Sandhya; Gupta, Manish; Wang, Bei; Lu, Dan; Krop, Ian E; Vogel, Charles L; Burris Iii, Howard A; LoRusso, Patricia M; Yi, Joo-Hee; Saad, Ola; Tong, Barbara; Chu, Yu-Waye; Holden, Scott; Joshi, Amita